RBC Capital analyst Gregory Renza maintained a Buy rating on ADC Therapeutics (ADCT – Research Report) on January 3 and set a price target of $6.00. The company’s shares closed yesterday at $2.03.
Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, IDEAYA Biosciences, and Amgen. According to TipRanks, Renza has an average return of 8.6% and a 46.46% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for ADC Therapeutics with a $3.33 average price target, representing a 64.04% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $5.75 and a one-year low of $0.36. Currently, ADC Therapeutics has an average volume of 580K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADC Therapeutics (ADCT) Company Description:
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company’s product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
Read More on ADCT:
- ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
- ADC Therapeutics regains compliance with NYSE continued listing standards
- ADC Therapeutics provides business updates
- ADC Therapeutics Provides Business Updates
- ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
